Resistance to vaccinia virus is less dependent on TNF under conditions of heterologous immunity

Journal of Immunology

Volumn 183, Issue 10, 2009, Pages 6554-6560

  Nie, Siwei ^a   Cornberg, Markus ^a,b   Selin, Liisa K ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOTOXIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CROSS REACTION; GENE DELETION; HETEROLOGOUS EXPRESSION; IMMUNITY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; VACCINIA VIRUS; VIRUS INFECTION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; ARENAVIRIDAE INFECTIONS; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOLOGIC MEMORY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOTOXIN-ALPHA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR-ALPHA; VACCINIA; VACCINIA VIRUS;

EID: 77951698300     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902156     Document Type: Article

References (40)

1. Herbein, G., and W. A. O'Brien. 2000. Tumor necrosis factor (TNF)-α and TNF receptors in viral pathogenesis. Proc. Soc. Exp. Biol. Med. 223: 241-257.
2. Schluter, D., and M. Deckert. 2000. The divergent role of tumor necrosis factor receptors in infectious diseases. Microbes Infect. 2: 1285-1292.
3. Calabrese, L. H., N. Zein, and D. Vassilopoulos. 2004. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann. Rheum. Dis. 63(Suppl 2): ii18-ii24.
4. Desai, S. B., and D. E. Furst. 2006. Problems encountered during anti-tumour necrosis factor therapy. Best Pract. Res. Clin. Rheumatol. 20: 757-790.
5. Welsh, R. M., and L. K. Selin. 2002. No one is naive: the significance of heterologous T-cell immunity. Nat. Rev. Immunol. 2: 417-426.
6. + T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J. Clin. Invest. 115: 3602-3612.
7. Urbani, S., B. Amadei, P. Fisicaro, M. Pilli, G. Missale, A. Bertoletti, and C. Ferrari. 2005. Heterologous T cell immunity in severe hepatitis C virus infection. J. Exp. Med. 201: 675-680.
8. Welsh, R. M., L. K. Selin, and E. Szomolanyi-Tsuda. 2004. Immunological memory to viral infections. Annu. Rev. Immunol. 22: 711-743.
9. Chen, H. D., A. E. Fraire, I. Joris, M. A. Brehm, R. M. Welsh, and L. K. Selin. 2001. Memory CD8+ T cells in heterologous antiviral immunity and immunopathology in the lung. Nat. Immunol. 2: 1067-1076.
10. Selin, L. K., S. M. Varga, I. C. Wong, and R. M. Welsh. 1998. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J. Exp. Med. 188: 1705-1715.
11. Cornberg, M., B. S. Sheridan, F. M. Saccoccio, M. A. Brehm, and L. K. Selin. 2007. Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry. J. Virol. 81: 934-944.
12. Kim, S. K., M. Cornberg, X. Z. Wang, H. D. Chen, L. K. Selin, and R. M. Welsh. 2005. Private specificities of CD8 T cell responses control patterns of heterologous immunity. J. Exp. Med. 201: 523-533.
13. Guidotti, L. G., T. Ishikawa, M. V. Hobbs, B. Matzke, R. Schreiber, and F. V. Chisari. 1996. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4: 25-36. (Pubitemid 26054933)
14. Hohler, T., A. Kruger, G. Gerken, P. M. Schneider, K. H. Meyer zum Buschenefelde, and C. Rittner. 1998. A tumor necrosis factor-α (TNF-α) promoter polymorphism is associated with chronic hepatitis B infection. Clin. Exp. Immunol. 111: 579-582.
15. Herbein, G., L. J. Montaner, and S. Gordon. 1996. Tumor necrosis factor α inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor. J. Virol. 70: 7388-7397. (Pubitemid 26339043)
16. Karsten, V., S. Gordon, A. Kirn, and G. Herbein. 1996. HIV-1 envelope glycoprotein gp120 down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor-α. Immunology 88: 55-60. (Pubitemid 26166376)
17. Di Marzio, P., J. Tse, and N. R. Landau. 1998. Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages. AIDS Res. Hum. Retroviruses 14: 129-138.
18. Sambhi, S. K., M. R. Kohonen-Corish, and I. A. Ramshaw. 1991. Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc. Natl. Acad. Sci. USA 88: 4025-4029.
19. Lidbury, B. A., I. A. Ramshaw, and S. K. Sambhi. 1995. The role for host-immune factors in the in vivo antiviral effects of tumour necrosis factor. Cytokine 7: 157-164.
20. Ruby, J., H. Bluethmann, and J. J. Peschon. 1997. Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J. Exp. Med. 186: 1591-1596.
21. Chan, F. K., J. Shisler, J. G. Bixby, M. Felices, L. Zheng, M. Appel, J. Orenstein, B. Moss, and M. J. Lenardo. 2003. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J. Biol. Chem. 278: 51613-51621.
22. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27: 493-497.
23. Ramshaw, I. A., A. J. Ramsay, G. Karupiah, M. S. Rolph, S. Mahalingam, and J. C. Ruby. 1997. Cytokines and immunity to viral infections. Immunol. Rev. 159: 119-135.
24. Cantin, E., B. Tanamachi, H. Openshaw, J. Mann, and K. Clarke. 1999. Gamma interferon (IFN-γ) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-γ ligand null-mutant mice. J. Virol. 73: 5196-5200. (Pubitemid 29246787)
25. Aggarwal, B. B., T. E. Eessalu, and P. E. Hass. 1985. Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon. Nature 318: 665-667.
26. Pimentel-Muinos, F. X., M. A. Munoz-Fernandez, and M. Fresno. 1994. Control of T lymphocyte activation and IL-2 receptor expression by endogenously secreted lymphokines. J. Immunol. 152: 5714-5722.
27. Sarin, A., M. Conan-Cibotti, and P. A. Henkart. 1995. Cytotoxic effect of TNF and lymphotoxin on T lymphoblasts. J. Immunol. 155: 3716-3718.
28. Zheng, L., G. Fisher, R. E. Miller, J. Peschon, D. H. Lynch, and M. J. Lenardo. 1995. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377: 348-351.
29. Kim, E. Y., and H. S. Teh. 2004. Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J. Immunol. 173: 4500-4509.
30. Singh, A., and M. Suresh. 2007. A role for TNF in limiting the duration of CTL effector phase and magnitude of CD8 T cell memory. J. Leukocyte Biol. 82: 1201-1211.
31. Munro, J. M., J. S. Pober, and R. S. Cotran. 1989. Tumor necrosis factor and interferon-γ induce distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio anubis. Am. J. Pathol. 135: 121-133.
32. Leist, T. P., and R. M. Zinkernagel. 1990. Treatment with anti-tumor necrosis factor alpha does not influence the immune pathological response against lymphocytic choriomeningitis virus. Cytokine 2: 29-34.
33. Feldmann, M., and R. N. Maini. 2001. Anti-TNF α therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19: 163-196.
34. Suenaert, P., V. Bulteel, L. Lemmens, M. Noman, B. Geypens, G. Van Assche, K. Geboes, J. L. Ceuppens, and P. Rutgeerts. 2002. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am. J. Gastroenterol. 97: 2000-2004.
35. Brehm, M. A., A. K. Pinto, K. A. Daniels, J. P. Schneck, R. M. Welsh, and L. K. Selin. 2002. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat. Immunol. 3: 627-634.
36. Selin, L. K., M. Y. Lin, K. A. Kraemer, D. M. Pardoll, J. P. Schneck, S. M. Varga, P. A. Santolucito, A. K. Pinto, and R. M. Welsh. 1999. Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity 11: 733-742.
37. Kettle, S., A. Alcami, A. Khanna, R. Ehret, C. Jassoy, and G. L. Smith. 1997. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1β-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1β-induced fever. J. Gen. Virol. 78(Pt 3): 677-685.
38. Reading, P. C., A. Khanna, and G. L. Smith. 2002. Vaccinia virus CrmE encodes a soluble and cell surface tumor necrosis factor receptor that contributes to virus virulence. Virology 292: 285-298.
39. Aggarwal, B. B. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3: 745-756.
40. Ellerin, T., R. H. Rubin, and M. E. Weinblatt. 2003. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum. 48: 3013-3022.